Experts name 2 ASX 200 blue chip shares to buy this week

I think quality ASX 200 blue-chip shares can be a great foundation for a portfolio.

But which ones could be buys right now?

Well, to narrow things down, let’s look at two that analysts at Morgans are recommending to investors this week, courtesy of The Bull.

Here’s what you need to know:

Morgans is positive on BHP and has named it as an ASX 200 blue-chip share to buy this week.

The broker likes the mining giant due to its portfolio of high quality mining assets, which leave it well-positioned to benefit from the long-term demand for copper and other critical minerals.

It expects the former to provide leverage to the electrification and decarbonisation megatrends. Morgans said:

BHP offers exposure to a portfolio of high quality mining assets and remains well positioned to benefit from long term demand for copper and other critical minerals. A strong operating performance, healthy cash generation and a disciplined approach to capital allocation continue to support the investment case. While iron ore remains important, increasing copper exposure provides leverage to electrification and decarbonisation trends. 

BHP appeals for potential capital growth, income and for diversified resources exposure. The company posted an attributable profit of $US9.8 billion in full year 2026, up 9 per cent on the prior corresponding period. Revenue of $US58.8 billion was up 15 per cent. BHP recently declared a final fully franked dividend of US99 cents a share.

The team at Morgans is also feeling positive about biotechnology giant CSL and has named it as an ASX 200 blue-chip share to buy now.

It likes CSL due to its strong competitive advantage in plasma therapies.

And while its performance has been disappointing in recent years, Morgans believes that its FY 2026 results could mark the bottom of the cycle.

The broker also likes CSL shares due to their defensive qualities and long-term growth outlook. It explains:

CSL is a global healthcare leader with strong competitive advantages across plasma therapies, vaccines and specialty medicines. Demand for its products remain largely independent of economic conditions. In our view, the latest full year result in 2026 is generating confidence that repeated earnings downgrades are behind CSL. With defensive earnings, global market leadership and attractive long term growth prospects, we view CSL as an appealing investment opportunity.